Vimukthini Peiris

Clinical Oncologist, proud Sri Lankan 🇱🇰

[The Sri Lanka College of Oncologists @slconcology]

The SLCO Regional Session in #Rathnapura, an initiative of the #YoungOncologistsForum of #SLCO, successfully brought together healthcare professionals through parallel #Oncology #Doctors' and #Nursing Sessions, promoting education, collaboration, and better #cancercare.

[Vimukthini Peiris @Vimukthini]

21st #AnnualAcedemicSessions of @slconcology kicks off to an auspicious start! @hiprabs @sidathwijeseke1

[Dr Amol Akhade @SuyogCancer]

Have u ever seen curves as wide as this for any drug recently? Lorlatinib for metastatic ALK positive NSCLC. Great results 👏. It works With reduced dose also. Let's hope it becomes more accessible. @asco #asco24 @OncoAlert @OncBrothers @Larvol @Alfdoc2 @JackWestMD @brunolarvol

[Krishan Jethwa @KrishanJethwa]

WOW!

HPV ctDNA detection at 3 months after dCRT for anal canal cancer associated with 100% risk of recurrence!

8% with HPV ctDNA negative

#ASCO24

[Yakup Ergün @dr_yakupergun]

MONARCH 3: Final overall survival results

🔍mFU: 8.1 years (OS: secondary endpoint)

mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06)

💥The absolute difference was 13.1 months but did not reach statistical significance

@Annals_Oncology @OncoAlert
https://t.co/EPZmdPNsBo

[Drew Moghanaki @DrewMoghanaki]

The standard of care for stage III NSCLC changes once again;

Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc

https://t.co/9KhukJ6iVL

[Rashid K. Sayyid @RKSayyid]

TiP: EA8211-SOAR: Non-inferiority phase 3 trial of SABR vs systemic therapy for metachronous (pre-treated) oligometastatic RCC (2-5 mets, IMDC fav-int risk)
🔷SABR arm: Systemic therapy only following progression
🔷Co-primary: OS & Gr≥3 toxicity
🔷Secondary: QoL, PFS, cost-effectiveness, ctDNA correlatives
@urotoday #GU24

[Nadeem Riaz @xrtGenomics]

1/N Finally out!! -- 30Gy for HPV+OPC in @JCO_ASCO
– work by the @MSKCancerCenter Head and Neck team, led by @imrtlee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm https://t.co/zHEaghVres

[The Sri Lanka College of Oncologists @slconcology]

✨Join us at NCISL where a star studded cast will discuss the latest advancements in #Oncology organised by the @CSSL_AAS and @slconcology in collaboration with @TataMemorial Centre #India✨
24th January 2024.
@prasaday @Dr_Pawan_Rane @Shrikhande_SV

[Massimo @Rainmaker1973]

In Sri Lanka there's this massive column of rock nearly 200 m high that hosts a 1600-year-old fortress on its top

[read more: https://t.co/PVr6Peg2KK]

[The Sri Lanka College of Oncologists @slconcology]

Wishing you a year filled with strength, resilience, and healing. Happy New Year!
#NewYear #2024NewYear

[Azzam Ameen @AzzamAmeen]

COLOMBO....🇱🇰

📸 @ThilinaKalu

[K Pavithran @drkpavithran]

Testicular cancer in 2023- a good review https://t.co/5Z9AsGUV4u…

[The Sri Lanka College of Oncologists @slconcology]

📌Watch our eminent consultant oncologist @nuradh speak on #breastcancer 🇱🇰
#BreastCancerAwareness
@adaderana
https://t.co/y3WPfAoAiY

[The Sri Lanka College of Oncologists @slconcology]

"No matter what obstacles we encounter, we owe it to our patients not to allow the high standards we have upheld thus far, to diminish. Therefore, excellence should remain our ultimate goal in all that we do"
Inspiring words by #SLCO president @prasaday
https://t.co/xoSqZ7j5XG

[Vimukthini Peiris @Vimukthini]

Honoured to have been given the #opportunity be a part of the 4th batch of #LeadershipDevelopment program of @faro_asia. Thank you #FARO and @slconcology!

[FARO_Asia @faro_asia]

Great teamwork with promising projects on education and research to boost membership engagement #LeadNext #FARO2023

[Nuradh Joseph @nuradh]

I've used this widely in my practice due to resource constraints with excellent results.. #hypofractionation #headandneckcancer @slconcology @slcancer @Vimukthini

[Shankar Siva @_ShankarSiva]

Twice daily radiotherapy to 54Gy BID ⬆️⬆️ OS and PFS in small cell #lungcancer as compared to 45Gy BID. compared to CONVERT and RTOG, higher once daily RT did not ⬆️ OS. #lcsm - abstract ➡️ https://t.co/buRrzton8c - time to change?

[Sumanta K. Pal, MD, FASCO @montypal]

This is absolutely brilliant. Not only is the data compelling, @_ShankarSiva, but it is presented in a manner that I feel may be quite conducive to sharing with my patients for discussion (thoughts, @LauraEsfeller @DebMaskens @RCCadvocate @advocatekidneys?). Your talk at #ASTRO23 not only validates a terrific option for pts 👏 but could provide all of us in academics a better way to practically convey information.

[The Sri Lanka College of Oncologists @slconcology]

October is #BreastCancer #Awareness month. The commonest cancer among women in #SriLanka it is eminently curable if detected early. @SlCancer @indira_trust #lka